Organisation paid for research Program year 2025 Source: CMS Open Payments

Center for Clinical Research

Neither a doctor nor a teaching hospital

Research payments

$3,381,596

660 payments

Through program year 2025, Center for Clinical Research is reported as receiving $3,381,596 in research payments, across 660 payments.

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$63,249	8
2024	Research	$462,047	32
2023	Research	$822,131	87
2022	Research	$653,147	111
2021	Research	$146,505	71
2020	Research	$111,875	59
2019	Research	$1,122,642	292

Breakdown

Who paid Research payments · program years 2019–2025

Molnlycke Health Care AB $995,099 9 payments
Boston Scientific Corporation $875,128 450 payments
GlaxoSmithKline, LLC. $354,624 100 payments
Nevro Corp. $310,788 18 payments
Avanos Medical $297,318 16 payments
Organogenesis Inc. $269,121 8 payments
Saluda Medical Americas, Inc. $211,934 47 payments
Genentech, Inc. $33,921 6 payments
Novartis Pharmaceuticals Corporation $32,136 3 payments
Celgene Corporation $1,000 1 payment

Studies the money was for Research payments · program years 2019–2025

DIPLO 01 / Mepilex UP $629,037 3 payments
Wavewriter Solis $561,024 107 payments
Post Market Observational Study $305,638 17 payments
A Prospective, Multi-center, Randomized, Assessor Blind, Controlled Study Comparing Lateral Branch Cooled Radiofrequency Denervation to Conservative Therapy as Treatment for Sacroiliac Joint Pain in a Military and Civilian Population. $297,318 16 payments
20 VLU 003 AFF study $269,121 8 payments
Exufiber AG+02 $212,831 4 payments
RSV Oa=Adj-002 $203,437 58 payments
Evoke Study $184,270 36 payments
Diplo NBF $149,762 1 payment
Wavewriter Solis $134,854 65 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.